Myelokathexis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for myelokathexis. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2036. Daily refresh.

1
Approved drugs
6
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Myelokathexis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

X4 Pharms 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating myelokathexis. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
36
3
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Xolremdi
MAVORIXAFOR
 X4 Pharms 6 62 — 2036-12-14

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11219621 Xolremdi method of use 75 2036-12-22
10610527 Xolremdi method of use 75 2036-12-22
10953003 Xolremdi formulation 55 2036-12-14
10548889 Xolremdi formulation 55 2038-12-11
12115156 Xolremdi formulation 55 2038-12-11
11045461 Xolremdi formulation 55 2038-12-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10548889 Xolremdi formulation 55 2038-12-11
12115156 Xolremdi formulation 55 2038-12-11
11045461 Xolremdi formulation 55 2038-12-11
10953003 Xolremdi formulation 55 2036-12-14
11219621 Xolremdi method of use 75 2036-12-22
10610527 Xolremdi method of use 75 2036-12-22

Related